SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors Meeting Abstract
| Authors: | Baselga, J.; Cortes, J.; De Laurentiis, M.; Dent, S.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y. H.; Jacot, W.; Krop, I. E.; Verma, S. |
| Abstract Title: | SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors |
| Meeting Title: | 2016 San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 77 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2016 Dec 6-10 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2017-02-01 |
| Language: | English |
| ACCESSION: | WOS:000397999000068 |
| DOI: | 10.1158/1538-7445.sabcs16-ot2-01-01 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT2-01-01 -- Source: Wos |
